Incyte Corp
Change company Symbol lookup
Select an option...
INCY Incyte Corp
ZSANQ Zosano Pharma Corp
BIPC Brookfield Infrastructure Corp
UTG Reaves Utility Income Trust
ARDLF Ardent Leisure Group Ltd
BFS Saul Centers Inc
ABB Abb Ltd
BURL Burlington Stores Inc
TNEN True North Energy Corp
H Hyatt Hotels Corp
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Closing Price
$74.13
Day's Change
0.40 (0.54%)
Bid
--
Ask
--
B/A Size
--
Day's High
74.95
Day's Low
73.28
Volume
(Below Average)
Volume:
1,291,741

10-day average volume:
1,508,909
1,291,741

Incyte to Present at Upcoming Investor Conference

8:00 am ET May 24, 2022 (BusinessWire) Print

Incyte (Nasdaq:INCY) announced today that it will present at the 43rd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 14, 2022 at 8:00 a.m. (PDT) /11 a.m. (EDT) in Rancho Palos Verdes.

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005029/en/

SOURCE: Incyte">

Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com 

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com
comtex tracking

COMTEX_407683762/1006/2022-05-24T08:00:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.